<DOC>
	<DOCNO>NCT01672957</DOCNO>
	<brief_summary>This observational study evaluate renal function participant underwent renal allograft transplantation start combined immunosuppressive treatment contain mycophenolate mofetil ( CellCept ) . Eligible participant follow 12 month follow transplantation .</brief_summary>
	<brief_title>An Observational Study Renal Function Kidney Transplant Participants Immunosuppressive Therapy Containing Mycophenolate Mofetil</brief_title>
	<detailed_description>The participant sample method use Orange study consecutive sampling , non-probability sample method participant meeting study 's inclusion exclusion criterion select enrol study pre-set sample size achieve . Thus , Orange study de novo kidney transplant participant , mycophenolate mofetil immunosuppressive combination therapy routine clinical practice , select consecutive manner ( non-probability sampling method ) meet inclusion/exclusion criterion 128 participant recruit study .</detailed_description>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Participants underwent renal allograft transplantation start combined immunosuppressive treatment contain mycophenolate mofetil accordance indication provide SmPC mycophenolate mofetil Date study enrollment date kidney transplantation Contraindication include SmPC capecitabine ( Xeloda ) prevail , like : Hypersensitivity active ingredient excipients product ; Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>